Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: A consensus report from the Valve Academic Research Consortium

European Heart Journal

Volumn 32, Issue 2, 2011, Pages 205-217

  Leon, Martin B ^a   Piazza, Nicolo ^a   Nikolsky, Eugenia ^a   Blackstone, Eugene H ^a   Cutlip, Donald E ^a   Kappetein, Arie Pieter ^a   Krucoff, Mitchell W ^a   MacK, Michael ^a   Mehran, Roxana ^a   Miller, Craig ^a   Morel, Marie Angéle ^a   Petersen, John ^a   Popma, Jeffrey J ^a   Takkenberg, Johanna J M ^a   Vahanian, Alec ^a   Van Es, Gerrit Anne ^a   Vranckx, Pascal ^a   Webb, John G ^a   Windecker, Stephan ^a   Serruys, Patrick W ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Transcatheter aortic valve implantation

Indexed keywords

ACUTE KIDNEY FAILURE; AORTA STENOSIS; AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; ARTERY CATHETERIZATION; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PERFORMANCE; CLINICAL ASSESSMENT; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CORONARY ARTERY OBSTRUCTION; ENDOCARDITIS; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VALVE PROSTHESIS; HUMAN; PATHOPHYSIOLOGY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; PUBLIC HEALTH; QUALITY CONTROL; SAFETY; STANDARDIZATION; STROKE; THERAPY EFFECT; TRANSCATHETER AORTIC VALVE IMPLANTATION;

ACUTE KIDNEY INJURY; AORTIC VALVE; AORTIC VALVE STENOSIS; CAUSE OF DEATH; ENDPOINT DETERMINATION; GRAFT OCCLUSION, VASCULAR; HEART CATHETERIZATION; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PROSTHESIS FAILURE; STROKE; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 78651489907     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq406     Document Type: Article

References (168)

1. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002;106:3006-3008.
2. Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Sebagh L, Bash A, Nusimovici D, Litzler PY, Bessou JP, Leon MB. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol 2004;43:698-703.
3. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231-1243.
4. Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardiovasc Surg 2006;132:1258-1261.
5. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg 2006;82:2111-2115.
6. Bramstedt KA. Aortic valve replacement in the elderly: frequently indicated yet frequently denied. Gerontology 2003;49:46-49.
7. Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, Tornos P, Gohlke-Barwolf C, Boersma E, Ravaud P, Vahanian A. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J 2005;26:2714-2720.
8. Piazza N, Yoshinobu O, De Jaegere P, Serruys PW. Guidelines for reporting cardiac mortality and morbidity after cardiac valve interventions-need for a reappraisal? Ann Thorac Surg 2009; 87:357-358.
9. Akins CW, Blackstone EH, Miller C, Kouchoukos NT, Turina MI. Guidelines for reporting cardiac mortality and morbidity after cardiac valve interventions- need for a reappraisal? (Response) Ann Thorac Surg 2009;87:359-360.
10. Thomas M, Wendler O. Transcatheter aortic valve implantation (TAVI): how to interpret the data and what data is required? EuroIntervention 2008;5:25-27.
11. Piazza N, Cutlip DE, Yoshinobu O, Kappetein AP, De Jaegere P, Serruys PW. Clinical endpoints in transcatheter aortic valve implantation: a call to ARC for standardised definitons. EuroIntervention 2008;5:28-29.
12. Akins CW, Miller DC, Turina MI et al. Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg 2008;135: 732-738.
13. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N. Universal defi- nition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-2195. (Pubitemid 350123680)
14. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351.
15. Antonini-Canterin F, Leiballi E, Capanna M, Burelli C, Cassin M, Macor F, Grandis U, Nicolosi GL. Association between carotid and coronary artery disease in patients with aortic valve stenosis: an angiographic study. Angiology 2009;60:596-600.
16. Kahlert P, Knipp SC, Schlamann M, Theilmann M, Al-Rashid F, Weber M, Johansson U, Wendt D, Jakob HG, Forsting M, Sack S, Erbel R, Eggebrecht H. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation 2010;121:870-878.
17. Ghanem A, Muller A, Nahle CP, Kocurek J, Werner N, Hammerstingl C, Schild HH, Schwab JO, Mellert F, Fimmers R, Nickenig G, Thomas D. Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol 2010;55:1427-1432.
18. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/ American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009;40: 2276-2293.
19. Saver JL. Proposal for a universal definition of cerebral infarction. Stroke 2008;39: 3110-3115.
20. Ong AT, Serruys PW, Mohr FW, Morice MC, Kappetein AP, Holmes DR Jr, Mack MJ, van den Brand M, Morel MA, van Es GA, Kleijne J, Koglin J, Russell ME. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J 2006;151:1194-1204.
21. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Buse JB, Cohen DJ, Mahoney E, Sleeper L, King S 3rd, Domanski M, McKinlay S, Fuster V. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial. Am Heart J 2008;155:215-223.
22. Gurm HS, Yadav JS, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Ansel G, Strickman NE, Wang H, Cohen SA, Massaro JM, Cutlip DE. Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med 2008;358:1572-1579.
23. Ringleb PA, Allenberg J, Bruckmann H, Eckstein HH, Fraedrich G, Hartmann M, Hennerici M, Jansen O, Klein G, Kunze A, Marx P, Niederkorn K, Schmiedt W, Solymosi L, Stingele R, Zeumer H, HackeW. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006;368:1239-1247.
24. Hobson RW II, Howard VJ, Roubin GS, Brott TG, Ferguson RD, Popma JJ, Graham DL, Howard G. Carotid artery stenting is associated with increased complications in octogenarians: 30-day stroke and death rates in the CREST lead-in phase. J Vasc Surg 2004;40:1106-1111.
25. Maggioni AP, Franzosi MG, Santoro E, White H, Van De Werf F, Tognoni G. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. N Engl J Med 1992;327:1-6.
26. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
27. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van De Werf F, Aylward PE, Topol EJ. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global use of strategies to open occluded coronary arteries. Circulation 1995;92:2811-2818.
28. Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146:431-438.
29. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157:805-810, 810 e1-2.
30. Totaro P, Toni D, Durastanti L, Bozzao L, Gualdi GF, Raz E, Kouleridou A, Pantano P. Diffusion-weighted MRI in patients with non-diagnostic CT in the post-acute phase of cerebral ischemia. Eur Neurol 2010;63:94-100.
31. Brott T, Adams HP Jr, Olinger CP, Adams HP Jr, Tomsick T, Barsan WG, Biller J, Eberle R, Hertzberg V, Walker M. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-870. (Pubitemid 19188240)
32. Bonita R, Beaglehole R. Modification of Rankin Scale: recovery of motor function after stroke. Stroke 1988;19:1497-1500.
33. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale. Extension to non-neurologists in the context of a clinical trial. Stroke 1997;28:307-310.
34. Lyden PD, Lau GT. A critical appraisal of stroke evaluation and rating scales. Stroke 1991;22:1345-1352.
35. Standardized Definitions for Cardiovascular Outcomes Trials: FDA Draft Recommendations (personal communication; 24 March 2010).
36. Manoukian SV, Voeltz MD, Eikelboom J. Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk. Clin Cardiol 2007;30:II24-II34.
37. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, Topol EJ, Manoukian SV. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol 2007;100:1364-1369.
38. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schömig A, Kastrati A. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008;51:690-697.
39. Budaj A, Eikelboom JW, Mehta SR, Afzal R, Chrolavicius S, Bassand JP, Fox KA, Wallentin L, Peters RJ, Granger CB, Joyner CD, Yusuf S; OASIS 5 Investigators. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2009;30:655-661.
40. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, Lansky AJ, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, Ohman EM. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009;30:1457-1466.
41. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, Stamler JS, Califf RM. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-1562.
42. Yang X, Alexander KP, Chen AY, Roe MT, Brindis RG, Rao SV, Gibler WB, Ohman EM, Peterson ED. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005;46: 1490-1495.
43. Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Stone GW. Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. JACC Cardiovasc Interv 2009;2:624-632.
44. Shishehbor MH, Madhwal S, Rajagopal V, Hsu A, Kelly P, Gurm HS, Kapadia SR, Lauer MS, Topol EJ. Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2009;2:46-53.
45. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673-682.
46. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
47. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855-1863.
48. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial: study design and rationale. Am Heart J 2008;156:44-56.
49. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/ non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
50. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-452.
51. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107: 238-244.
52. Blazing MA, De Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004;292:55-64. (Pubitemid 38923794)
53. SYNERGY Executive Committee. The SYNERGY trial: study design and rationale. Am Heart J 2002;143:952-960.
54. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354: 1464-1476.
55. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, De Feyter PJ, Vahanian A, Topol EJ. Longterm efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703.
56. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 2004;148:764-775.
57. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, Pollack CV Jr, Peterson ED, Alexander KP. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation 2009;119:1873-1882.
58. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S. Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 2008;156: 1080-1088 e1.
59. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605.
60. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-694.
61. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275:1489-1494.
62. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
63. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998;128:194-203.
64. Gruberg L, Mintz GS, Mehran R, Dangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36: 1542-1548.
65. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-1119.
66. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-936.
67. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.
68. Antunes PE, Prieto D, Ferrao De Oliveira J, Antunes MJ. Renal dysfunction after myocardial revascularization. Eur J Cardiothorac Surg 2004;25:597-604.
69. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, Hiesmayr M. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 2004; 15:1597-1605.
70. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;16:3365-3370.
71. Aregger F, Wenaweser P, Hellige GJ, Kadner A, Carrel T, Windecker S, Frey FJ. Risk of acute kidney injury in patients with severe aortic valve stenosis undergoing transcatheter valve replacement. Nephrol Dial Transplant 2009;24: 2175-2179.
72. Bagur R, Webb JG, Nietlispach F, Dumont E, De Larochelliere R, Doyle D, Masson JB, Gutierrez MJ, Clavel MA, Bertrand OF, Pibarot P, Rodes-Cabau J. Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement. Eur Heart J 2010;31:865-874.
73. Lameire N, Van Biesen W, Vanholder R. The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol 2006;2:364-377.
74. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure defi- nition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-R212.
75. Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: physiological principles. Intensive Care Med 2004;30:33-37. (Pubitemid 38147105)
76. Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002;8:509-514.
77. Abosaif NY, Tolba YA, Heap M, Russell J, El Nahas AM. The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. Am J Kidney Dis 2005;46:1038-1048.
78. Bell M, Liljestam E, Granath F, Fryckstedt J, Ekbom A, Martling CR. Optimal follow-up time after continuous renal replacement therapy in actual renal failure patients stratified with the RIFLE criteria. Nephrol Dial Transplant 2005; 20:354-360.
79. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006;10:R73.
80. Kuitunen A, Vento A, Suojaranta-Ylinen R, Pettila V. Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. Ann Thorac Surg 2006;81: 542-546.
81. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006;34:1913-1917. (Pubitemid 43982467)
82. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
83. Guitterez NV, Diaz A, Timmis GC, O'Neill WW, Stevens MA, Sandberg KR, McCullough PA. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol 2002;15:349-354.
84. Van Mieghem NM, Nuis RJ, Piazza N, Apostolos T, Ligthart J, Schultz C, De Jaegere PP, Serruys PW. Vascular complications with transcatheter aortic valve implantation using the 18 Fr Medtronic CoreValve System(R): the Rotterdam experience. EuroIntervention 2010;5:673-679.
85. Ducrocq G, Francis F, Serfaty JM, Himbert D, Maury JM, Pasi N, Marouene S, Provenchere S, Iung B, Castier Y, Leseche G, Vahanian A. Vascular complications of transfemoral aortic valve implantation with the Edwards SAPIEN prosthesis: incidence and impact on outcome. EuroIntervention 2010;5:666-672.
86. Tchetche D, Dumonteil N, Sauguet A, Descoutures F, Luz A, Garcia O, Soula P, Gabiache Y, Fournial G, Marcheix B, Carrie D, Fajadet J. Thirty-day outcome and vascular complications after transarterial aortic valve implantation using both Edwards Sapien and Medtronic CoreValve(R) bioprostheses in a mixed population. EuroIntervention 2010;5:659-665.
87. Kahlert P, Al-Rashid F, Weber M, Wendt D, Heine T, Kottenberg E, Thielmann M, Kuhl H, Peters J, Jakob HG, Sack S, Erbel R, Eggebrecht H. Vascular access site complications after percutaneous transfemoral aortic valve implantation. Herz 2009;34:398-408.
88. Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK, Bernhard VM, Matsumura JS, May J, Veith FJ, Fillinger MF, Rutherford RB, Kent KC. Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg 2002;35: 1048-1060. (Pubitemid 46098517)
89. Bleiziffer S, Ruge H, Mazzitelli D, Hutter A, Opitz A, Bauernschmitt R, Lange R. Survival after transapical and transfemoral aortic valve implantation: talking about two different patient populations. J Thorac Cardiovasc Surg 2009;138: 1073-1080.
90. Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS, Grayburn PA, Khandheria BK, Levine RA, Marx GR, Miller FA Jr., Nakatani S, Quinones MA, Rakowski H, Rodriguez LL, Swaminathan M, Waggoner AD, Weissman NJ, Zabalgoitia M. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 2009;22:975-1014; quiz 1082-4.
91. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007;28:230-268.
92. Bonow RO, Carabello BA, Chatterjee K, De Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS. Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008;118:e523-e661.
93. Schultz CJ, Weustink A, Piazza N, Otten A, Mollet N, Krestin G, van Geuns RJ, De Feyter P, Serruys PW, De Jaegere P. Geometry and degree of apposition of the CoreValve ReValving system with multislice computed tomography after implantation in patients with aortic stenosis. J Am Coll Cardiol 2009;54:911-918.
94. Schultz C, Piazza N, van Geuns RJ, De Feyter P, Serruys P, De Jaegere P. Tips and Tricks for Imaging Percutaneously Implanted Aortic Valve Prostheses. New York: Informa Healthcare, 2010. p275-287.
95. Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Nercolini D, Tapiero S, Litzler PY, Bessou JP, Babaliaros V. Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. J Am Coll Cardiol 2006;47:1214-1223.
96. Webb JG, Altwegg L, Boone RH, Cheung A, Ye J, Lichtenstein S, Lee M, Masson JB, Thompson C, Moss R, Carere R, Munt B, Nietlispach F, Humphries K. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation 2009;119:3009-3016.
97. Eberhard Grube LB, Ralf M, Barthel S, Bernfried Z, Dinesh N, Harald B, Thomas F, Stein I, Ulrich G. Progress and current status of percutaneous aortic valve replacement: results of three device generations of the corevalve revalving system. Circ Cardiovasc Intervent 2008;1:167-175.
98. Piazza N, Grube E, Gerckens U, den Heijer P, Linke A, Luha O, Ramondo A, Ussia G, Wenaweser P, Windecker S, Laborde JC, De Jaegere P, Serruys PW. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention 2008;4:242-249.
99. Walther T, Simon P, Dewey T, Wimmer-Greinecker G, Falk V, Kasimir MT, Doss M, Borger MA, Schuler G, Glogar D, Fehske W, Wolner E, Mohr FW, Mack M. Transapical minimally invasive aortic valve implantation: multicenter experience. Circulation 2007;116:1240-1245.
100. Svensson LG, Dewey T, Kapadia S, Roselli EE, Stewart A, Williams M, Anderson WN, Brown D, Leon M, Lytle B, Moses J, Mack M, Tuzcu M, Smith C. United States feasibility study of transcatheter insertion of a stented aortic valve by the left ventricular apex. Ann Thorac Surg 2008;86:46-54.
101. Himbert D, Descoutures F, Al-Attar N, Iung B, Ducrocq G, Détaint D, Brochet E, Messika-Zeitoun D, Francis F, Ibrahim H, Nataf P, Vahanian A. Results of transfemoral or transapical aortic valve implantation following a uniform assessment in high-risk patients with aortic stenosis. J Am Coll Cardiol 2009;54:303-311.
102. De Jaegere P, Piazza N, Galema T, Otten A, Soliman O, Van Dalen B, Geleijnse M, Kappetein A, Garcia Garcia H, Van Es G, Serruys P. Early echocardiographic evaluation following percutaneous implantation with the selfexpanding CoreValve ReValving System aortic valve bioprosthesis. Eurointervention 2008;4:351-357.
103. Detaint D, Lepage L, Himbert D, Brochet E, Messika-Zeitoun D, Iung B, Vahanian A. Determinants of significant paravalvular regurgitation after transcatheter aortic valve: implantation impact of device and annulus discongruence. JACC Cardiovasc Interv 2009;2:821-827.
104. Clavel MA, Webb JG, Pibarot P, Altwegg L, Dumont E, Thompson C, De Larochellière R, Doyle D, Masson JB, Bergeron S, Bertrand OF, Rodés-Cabau J. Comparison of the hemodynamic performance of percutaneous and surgical bioprostheses for the treatment of severe aortic stenosis. J Am Coll Cardiol 2009;53:1883-1891.
105. Davila-Roman VG, Waggoner AD, Kennard ED, Holubkov R, Jamieson WR, Englberger L, Carrel TP, Schaff HV. Prevalence and severity of paravalvular regurgitation in the Artificial Valve Endocarditis Reduction Trial (AVERT) echocardiography study. J Am Coll Cardiol 2004;44:1467-1472.
106. Ionescu A, Fraser AG, Butchart EG. Prevalence and clinical significance of incidental paraprosthetic valvar regurgitation: a prospective study using transoesophageal echocardiography. Heart 2003;89:1316-1321.
107. O'Rourke DJ, Palac RT, Malenka DJ, Marrin CA, Arbuckle BE, Plehn JF. Outcome of mild periprosthetic regurgitation detected by intraoperative transesophageal echocardiography. J Am Coll Cardiol 2001;38:163-166.
108. Rallidis LS, Moyssakis IE, Ikonomidis I, Nihoyannopoulos P. Natural history of early aortic paraprosthetic regurgitation: a five-year follow-up. Am Heart J 1999;138:351-357.
109. Kupferwasser II, Mohr-Kahaly S, Erbel R, Nolting A, Dohmen G, Oelert H, Meyer J. Improved assessment of pathological regurgitation in patients with prosthetic heart valves by multiplane transesophageal echocardiography. Echocardiography 1997;14:363-374.
110. Mohr-Kahaly S, Kupferwasser I, Erbel R, Oelert H, Meyer J. Regurgitant flow in apparently normal valve prostheses: improved detection and semiquantitative analysis by transesophageal two-dimensional color-coded Doppler echocardiography. J Am Soc Echocardiogr 1990;3:187-195.
111. Mohr-Kahaly S, Kupferwasser I, Erbel R, Wittlich N, Iversen S, Oelert H, Meyer J. Value and limitations of transesophageal echocardiography in the evaluation of aortic prostheses. J Am Soc Echocardiogr 1993;6:12-20.
112. Trepels T, Martens S, Doss M, Fichtlscherer S, Schachinger V. Images in cardiovascular medicine. Thrombotic restenosis after minimally invasive implantation of aortic valve stent. Circulation 2009;120:e23-e24.
113. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994;96:200-209.
114. Comoglio C, Boffini M, El Qarra S, Sansone F, D'Amico M, Marra S, Rinaldi M. Aortic valve replacement and mitral valve repair as treatment of complications after percutaneous core valve implantation. J Thorac Cardiovasc Surg 2009;138: 1025-1027.
115. Wong DR, Boone RH, Thompson CR, Allard MF, Altwegg L, Carere RG, Cheung A, Ye J, Lichtenstein SV, Ling H, Webb JG. Mitral valve injury late after transcatheter aortic valve implantation. J Thorac Cardiovasc Surg 2009;137: 1547-1549.
116. Piazza N, Marra S, Webb J, D'Amico M, Rinaldi M, Boffini M, Comoglio C, Scacciatella P, Kappetein A, De Jaegere P, Serruys P. Two cases of Aneurysm of the Anterior Mitral Valve Leaflet associated with Transcatheter Aortic Valve Endocarditis (TAVE): a mere coincidence? J Cardiothorac Surg 2010;140: e36-8. Published online ahead of print 18 February 2010.
117. Piazza N, De Jaegere P, Schultz C, Becker AE, Serruys PW, Anderson RH. Anatomy of the aortic valvar complex and its implications for transcatheter implantation of the aortic valve. Circ Cardiovasc Intervent 2008;1:74-81.
118. Moreno R, Dobarro D, Lopez De Sa E, Prieto M, Morales C, Calvo Orbe L, Moreno-Gomez I, Filgueiras D, Sanchez-Recalde A, Galeote G, Jimenez-Valero S, Lopez-Sendon JL. Cause of complete atrioventricular block after percutaneous aortic valve implantation: insights from a necropsy study. Circulation 2009;120:e29-e30.
119. El-Khally ZTB, Staniloae C, Theroux P, Dubuc M, Roy D, Guerra P, Macle L, Talajic M. Prognostic significance of newly acquired bundle branch block after aortic valve replacement. Am J Cardiol 2004;94:1008-1011.
120. Thomas JL, Dickstein RA, Parker FB Jr., Potts JL, Poirier RA, Fruehan CT, Eich RH. Prognostic significance of the development of left bundle conduction defects following aortic valve replacement. J Thorac Cardiovasc Surg 1982;84: 382-386.
121. Limongelli G, Ducceschi V, D'Andrea A, Renzulli A, Sarubbi B, De Feo M, Cerasuolo F, Calabro R, Cotrufo M. Risk factors for pacemaker implantation following aortic valve replacement: a single centre experience. Heart 2003;89: 901-904.
122. Gordon RS, Ivanov J, Cohen G, Ralph-Edwards AL. Permanent cardiac pacing after a cardiac operation: predicting the use of permanent pacemakers. Ann Thorac Surg 1998;66:1698-1704.
123. Dawkins S, Hobson AR, Kalra PR, Tang AT, Monro JL, Dawkins KD. Permanent pacemaker implantation after isolated aortic valve replacement: incidence, indications, and predictors. Ann Thorac Surg 2008;85:108-112.
124. Sinhal A, Altwegg L, Pasupati S, Allard M, Martin P, Cheung A, Ye J, Kerr C, Lichenstein SV, Webb JG. Atrioventricular block after transcatheter balloon expandable aortic valve implantation. JACC Cardiovasc Interv 2008;1:305-309.
125. Jilaihawi H, Chin D, Vasa-Nicotera M, Jeilan M, Spyt T, Ng GA, Bence J, Logtens E, Kovac J. Predictors for permanent pacemaker requirement after transcatheter aortic valve implantation with the CoreValve bioprosthesis. Am Heart J 2009;157:860-866.
126. Calvi V, Puzzangara E, Pruiti GP, Conti S, Di Grazia A, Ussia GP, Capodanno D, Tamburino C. Early conduction disorders following percutaneous aortic valve replacement. Pacing Clin Electrophysiol 2009;32 Suppl 1:S126-S130.
127. Gutierrez M, Rodes-Cabau J, Bagur R, Doyle D, DeLarochelliere R, Bergeron S, Lemieux J, Villeneuve J, Cote M, Bertrand OF, Poirier P, Clavel MA, Pibarot P, Dumont E. Electrocardiographic changes and clinical outcomes after transapical aortic valve implantation. Am Heart J 2009;158:302-308.
128. Piazza N, Onuma Y, Jesserun E, Kint PP, Maugenest AM, Anderson RH, De Jaegere P, Serruys PW. Early and persistent intraventricular conduction abnormalities and requirements for pacemaking after percutaneous replacement of the aortic valve. JACC Cardiovasc Interv 2008;1:310-316.
129. Orlowska-Baranowska E, Baranowski R, Michalek P, Hoffman P, Rywik T, Rawczylska-Englert I. Prediction of paroxysmal atrial fibrillation after aortic valve replacement in patients with aortic stenosis: identification of potential risk factors. J Heart Valve Dis 2003;12:136-141.
130. Banach M, Goch A, Misztal M, Rysz J, Jaszewski R, Goch JH. Predictors of paroxysmal atrial fibrillation in patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg 2007;134:1569-1576.
131. Webb JG, Pasupati S, Humphries K, Thompson C, Altwegg L, Moss R, Sinhal A, Carere RG, Munt B, Ricci D, Ye J, Cheung A, Lichtenstein SV. Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation 2007;116:755-763.
132. Webb JG. Coronary obstruction due to transcatheter valve implantation. Catheter Cardiovasc Interv 2009;73:973.
133. Al-Attar N, Ghodbane W, Himbert D, Rau C, Raffoul R, Messika-Zeitoun D, Brochet E, Vahanian A, Nataf P. Unexpected complications of transapical aortic valve implantation. Ann Thorac Surg 2009;88:90-94.
134. Tzikas A, Schultz C, Piazza N, van Geuns RJ, Serruys PW, De Jaegere PP. Perforation of the membranous interventricular septum after transcatheter aortic valve implantation. Circ Cardiovasc Interv 2009;2:582-583.
135. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-e479.
136. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-923.
137. Little B (ed.). The Criteria Committee of the New York Heart Association. Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis. 6th ed. Boston: Little, Brown, 1964. Boston, 1964.
138. Group TE. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
139. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-M156.
140. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245-1255.
141. Brooks R, Rabin R, De Charro F (eds) The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective: Evidence from the EuroQol BIO MED Research Programme. Rotterdam: Kluwer Academic Publishers; 2003. 2003.
142. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, McCullough PA, Pina I, Tooley J,Weintraub WS, Rumsfeld JS. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J 2005; 150:707-715. (Pubitemid 41396503)
143. Ussia GP, Mule M, Barbanti M, Cammalleri V, Scarabelli M, Imme S, Capodanno D, Ciriminna S, Tamburino C. Quality of life assessment after percutaneous aortic valve implantation. Eur Heart J 2009;30:1790-1796.
144. Winograd CH, Gerety MB, Chung M, Goldstein MK, Dominguez F Jr, Vallone R. Screening for frailty: criteria and predictors of outcomes. J Am Geriatr Soc 1991; 39:778-784.
145. Hamerman D. Toward an understanding of frailty. Ann Intern Med 1999;130: 945-950.
146. Lee DH, Buth KJ, Martin BJ et al. Frail patients are at increased risk for mortality and prolonged institutional care after cardiac surgery. Circulation 2010;121: 973-978.
147. Disability and frailty among elderly Canadians: a comparison of six surveys. Int Psychogeriatr 2001;13 Supp 1:159-167.
148. Chin APMJ, De Groot LC, van Gend SV, Schoterman MH, Schouten EG, Schroll M, van StaverenWA. Inactivity and weight loss: effective criteria to identify frailty. J Nutr Health Aging 2003;7:55-60.
149. Walther T, Falk V, Kempfert J, Borger MA, Fassl J, Chu MW, Schuler G, Mohr FW. Transapical minimally invasive aortic valve implantation; the initial 50 patients. Eur J Cardiothorac Surg 2008;33:983-988.
150. Webb JG, Chandavimol M, Thompson CR, Ricci DR, Carere RG, Munt BI, Buller CE, Pasupati S, Lichtenstein S. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006;113:842-850.
151. Ferrari E, Rizzo E, Sulzer C, von Segesser LK. Unexpected left ventricular freewall rupture following an aortic catheter-valve implantation. Eur J Cardiothorac Surg. 2010;37:242-244. Published online ahead of print 19 August 2009.
152. Maroto LC, Rodriguez JE, Cobiella J, Silva J. Delayed dislocation of a transapically implanted aortic bioprosthesis. Eur J Cardiothorac Surg 2009;36:935-937.
153. Clavel MA, Dumont E, Pibarot P, Doyle D, De Larochelliere R, Villeneuve J, Bergeron S, Couture C, Rodes-Cabau J. Severe valvular regurgitation and late prosthesis embolization after percutaneous aortic valve implantation. Ann Thorac Surg 2009;87:621-623.
154. Ruiz C, Laborde J, Condado J, Chiam P, Condado J. First percutaneous transcatheter aortic valve-in-valve implant with three year follow-up. Catheter Cardiovasc Interv 2008;72:143-148.
155. Piazza N, Schultz C, De Jaegere PP, Serruys PW. Implantation of two selfexpanding aortic bioprosthetic valves during the same procedure-Insights into valve-in-valve implantation ('Russian doll concept'). Catheter Cardiovasc Interv 2009;73:530-539.
156. Montorsi P, De Bernardi F, Muratori M, Cavoretto D, Pepi M. Role of cine- fluoroscopy, transthoracic, and transesophageal echocardiography in patients with suspected prosthetic heart valve thrombosis. Am J Cardiol 2000;85:58-64.
157. Cianciulli TE, Lax JA, Beck MA, Cerruti FE, Gigena GE, Saccheri MC, Fernandez E, Dorelle AN, Leguizamon JH, Prezioso HA. Cinefluoroscopic assessment of mechanical disc prostheses: its value as a complementary method to echocardiography. J Heart Valve Dis 2005;14:664-673.
158. Piazza N, Grube E, Gerckens U, Schuler G, Linke A, den Heijer P, Kovacs J, Spyt T, Laborde J, Morel M, Nuis R, Garcia-Garcia H, De Jaegere P, Serruys P. A clinical protocol for analysis of the structural integrity of the Medtronic CoreValve System(R) frame and its application in patients with 1-year minimum follow-up. EuroIntervention 2010;5:680-686.
159. Thyregod HG, Lund JT, Engstrøm T, Steinbruchel DA. Transcatheter aortic valve prosthesis surgically replaced 4 months after implantation. Eur J Cardiothorac Surg 2010;37:494-496.
160. Rosengart TK, Feldman T, Borger MA, Vassiliades TA Jr, Gillinov AM, Hoercher KJ, Vahanian A, Bonow RO, O'Neill W; American Heart Association Council on Cardiovascular Surgery and Anesthesia; American Heart Association Council on Clinical Cardiology; Functional Genomics and Translational Biology Interdisciplinary Working Group; Quality of Care and Outcomes Research Interdisciplinary Working Group. Percutaneous and minimally invasive valve procedures: a scientific statement from the American Heart Association Council on Cardiovascular Surgery and Anesthesia, Council on Clinical Cardiology, Functional Genomics and Translational Biology Interdisciplinary Working Group, and Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2008;117:1750-1767.
161. Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, Cribier A, De Jaegere P, Fournial G, Kappetein AP, Kovac J, Ludgate S, Maisano F, Moat N, Mohr F, Nataf P, Piérard L, Pomar JL, Schofer J, Tornos P, Tuzcu M, van Hout B, Von Segesser LK, Walther T; European Association of Cardio-Thoracic Surgery; European Society of Cardiology; European Association of Percutaneous Cardiovascular Interventions. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2008;29:1463-1470.
162. Buellesfeld L, Gerckens U, Grube E. Percutaneous implantation of the first repositionable aortic valve prosthesis in a patient with severe aortic stenosis. Catheter Cardiovasc Interv 2008;71:579-584.
163. Schofer J, Schluter M, Treede H, Franzen OW, Tübler T, Pascotto A, Low RI, Bolling SF, Meinertz T, Reichenspurner H. Retrograde transarterial implantation of a nonmetallic aortic valve prosthesis in high-surgical-risk patients with severe aortic stenosis: a first-in-man feasibility and safety study. Circ Cardiovasc Interv 2008;1:126-133.
164. Nietlispach F, Wijesinghe N, Wood D, Carere RG, Webb JG. Current balloon-expandable transcatheter heart valve and delivery systems. Catheter Cardiovasc Interv 2010;75:295-300.
165. Falk V, Schwammenthal EE, Kempfert J, Linke A, Schuler G, Mohr FW, Walther T. New anatomically oriented transapical aortic valve implantation. Ann Thorac Surg 2009;87:925-926.
166. Feldman T, Wasserman HS, Herrmann HC, Gray W, Block PC, Whitlow P, St Goar F, Rodriguez L, Silvestry F, Schwartz A, Sanborn TA, Condado JA, Foster E. Percutaneous mitral valve repairusing the edge-to-edge technique: sixmonth results of the EVEREST Phase 1 Clinical trial. J Am Coll Cardiol 2005;46: 2134-2140.
167. Feldman T, Kar S, Rinaldi M, Fail P, Hermiller J, Smalling R, Whitlow PL, Gray W, Low R, Herrmann HC, Lim S, Foster E, Glower D; EVEREST Investigators. Percutaneous mitral repair with the MitraClip system: safety and mid-term durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 2009;54:686-694.
168. Feldman T, Mauri L, Foster E, Glower D, on behalf of the EVEREST II Investigators. Endovascular valve edge-to-edge repair study (EVEREST II) randomized clinical trial: primary safety and efficacy endpoints. ACC late breaking clinical trial (March 14, 2010).